← Back

Guangdong Jiaying Pharmaceutical Co Ltd

Guangdong Jiaying Pharmaceutical Co., Ltd. researches, develops, produces, and sells Chinese patent medicines in Mainland China. Its products primarily treat throat ailments, colds, orthopedic conditions, rheumatism, gynecological conditions, hepatobiliary diseases, and gastrointestinal disorders, and also include tonics. The company was founded in 2003 and is based in Meizhou, China.

Country
Price · split & dividend adjusted
News & notes moving 002198.CS
002198.CS

ST Jiaying's finance chief Zeng Yong resigns, Zhang Peng takes over duties temporarily

Guangdong Jiaying Pharmaceutical Co., Ltd., listed as ST Jiaying, announced that finance chief Zeng Yong has resigned for personal reasons. After resigning, he will no longer hold any position in the company or its subsidiaries, and his resignation report takes effect from the date it is delivered to the board of directors. As of the announcement date, Zeng Yong does not hold any company shares and has completed the financial handover work. His resignation does not affect the company's daily operations. Before a new finance chief is appointed, Zhang Peng, head of the accounting department, will perform the duties of finance chief, and the company will complete the appointment process as soon as possible.
002198.CS
Jiemian·15dRead more →
002198.CS▼

ST Jiaying's 2026 interim report shows a net loss of 12.98 million yuan, swinging from profit to loss year-on-year

ST Jiaying released its 2026 interim report. Total operating revenue was 166 million yuan, down 16.68% year-on-year. Net profit attributable to the parent company was a loss of 12.98 million yuan, swinging from profit to loss year-on-year, a decline of 164.63%. Net cash flow from operating activities was a negative 54.80 million yuan, a decrease of 29.41 million yuan year-on-year. The company's asset-liability ratio was 16.80%, gross margin was 53.21%, return on equity was negative 1.84%, and diluted earnings per share was negative 0.03 yuan. The number of shareholders was 19,400, and the top ten shareholders held 35.07% of the total share capital.
002198.CS ▼
Jiemian·24dRead more →
002198.CS▼

ST Jiaying posts first-half net loss of 12.98 million yuan, down 164.6% year on year

ST Jiaying released its 2026 interim report. Operating revenue was 166 million yuan, down 16.7% year on year. Net loss attributable to the parent was 12.98 million yuan, down 164.6% year on year. Net loss attributable to the parent after deducting non-recurring items was 13.85 million yuan, down 173.7% year on year. Net operating cash flow was negative 54.8 million yuan, down 115.9% year on year. Fully diluted earnings per share was negative 0.0256 yuan. In the second quarter, operating revenue was 42.83 million yuan, down 44.6% year on year. Net loss attributable to the parent was 25.44 million yuan, down 643.6% year on year. Net loss attributable to the parent after deducting non-recurring items was 26.13 million yuan, down 960.1% year on year. Earnings per share was negative 0.0501 yuan. As of the end of the second quarter, total assets were 847 million yuan, down 0.2% from the end of the previous year. Net assets attributable to the parent were 705 million yuan, down 1.8% from the end of the previous year. The company said in the interim report that its main business remains the research, development, production and sale of Chinese patent medicines, covering categories such as throat medicines, cold medicines, orthopaedic medicines, heat-clearing medicines and tonic medicines, and that its leading products continue to hold a certain market share and brand influence.
002198.CS ▼
财中社·25dRead more →
© 2026 MarketDXAsset